TD Cowen upgrades Tempus AI stock rating on stronger fundamentals By Investing.com

TD Cowen upgraded Tempus AI to Buy and cut its price target to $65 from $70, citing strengthened fundamentals after the stock fell 54.6% over six months to $42.94. The firm expects the Insights business to accelerate growth in 2026, aided by rising pharma demand for AI research and development tools, while Genomics may also provide upside. Tempus AI remains unprofitable, but recent partnership expansion with Gilead and Merck supports the long-term growth case.

Analysis

The upgrade is less a valuation call than a signal that the market has likely over-discounted the optionality in Tempus’ data monetization engine. If the Insights business inflects in 2026 as expected, the stock behaves less like a single-product healthcare IT name and more like a high-multiple data platform with operating leverage: incremental gross profit should scale faster than revenue once inference/research workflows are embedded into pharma R&D budgets. That makes the next two quarters about conviction-building rather than near-term earnings, because the catalyst path is mostly contract wins, usage expansion, and proof that the dataset compounds.

The second-order winner here is GILD and other large pharmas, which gain a cheaper/faster discovery layer and can externalize more early-stage R&D spend to a vendor with expanding proprietary data access. The competitive loser is not another public AI company so much as traditional CROs and niche genomics tools that compete on fragmented datasets; Tempus can bundle clinical workflow, genomics, and AI analytics in a way that raises switching costs. The key risk is that partner announcements can inflate narrative without translating into measurable billings, so investors should watch for conversion of collaborations into recurring usage and backlog over the next 2-4 quarters.

Consensus may be underestimating how much of the upside is already tied to gross margin inflection, not revenue growth alone. A 50% drawdown can still leave the stock expensive if losses persist, but it also creates a favorable setup if management shows even modest operating discipline and evidence of sales efficiency. The main contrarian takeaway is that the right trade may be to own the platform while fading the broader healthcare software basket, since Tempus has a clearer path to becoming a category aggregator rather than just another AI-enabled vendor.

For GILD, the market is likely treating the Tempus collaboration as incremental rather than strategically important; if AI-assisted biomarker discovery shortens trial design cycles, the real upside is multiple years out and embedded in R&D productivity, not immediate revenue. That makes this a better long-duration strategic signal for biotech productivity than a near-term earnings catalyst.

Key Decisions for Investors

• Initiate a tactical long TEM position on pullbacks toward the low-$40s with a 3-6 month horizon; target a re-rating toward the low-$50s if 2026 growth commentary improves, but cut if partner monetization fails to show up in booked revenue by the next two quarterly prints.
• Pair trade: long TEM / short a basket of lower-momentum healthcare software or CRO names over the next 2 quarters; the thesis is that Tempus has more credible data-network optionality and a cleaner path to margin leverage than fragmented peers.
• Buy GILD on weakness as a medium-term beneficiary of improved R&D productivity from Tempus partnerships; expect limited 1-quarter earnings impact, but potential strategic upside if external AI tools reduce discovery cycle times over 12-24 months.
• Use call spreads rather than stock for TEM into the next earnings cycle, as the key risk is narrative reversal from lack of near-term profitability; upside is meaningful if the market starts pricing 2026 operating leverage, while downside is capped by defined premium.
• Set a watchlist trigger for any evidence of expanding recurring usage metrics, not just new collaborations; if conversion stalls over 2 quarters, reduce or exit the long because the stock is still vulnerable to 'AI story, weak monetization' compression.